NGNE Stock — Neurogene Inc.: Cash, EV, Pipeline

Share price

$32.09

Market cap

$642.2M

Cash

$360.2M

Enterprise value

$282.0M

Balance sheet

Cash	$360.2M
Debt	$0.0M
Net cash	$360.2M
Enterprise value	$282.0M
Basic shares	15.8M shares
Fully diluted shares	31.8M shares
Fully diluted market cap	$1,021.5M
Cash per share	$22.80

Cash figures as of 2026-07-02. Database snapshot: 2026-09-21.

Price history

Loading NGNE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	NGN-401	Phase 3	Rett Syndrome	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

NGN-401

Phase 3 · Active Modality: Gene therapy with EXACT transgene regulation technology

Target MECP2

Partnerships University of Edinburgh: exclusive worldwide license to EXACT technology and optimized MECP2 cassettes (Mar 2022); up to $5.3M regulatory milestones ($0.3M paid for Phase 1/2), up to $25M sales milestones, low single-digit royalties

Indications

Rett syndrome (females) (Stage not disclosed)

Status note First clinical-stage program using EXACT technology. Completed dosing in Phase 1/2 trial for Rett syndrome and completed dosing in the registrational Embolden study (single-arm, baseline-controlled, open-label in females with Rett syndrome), designed to support a potential BLA submission.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NGN-401
Lead indication	Rett Syndrome
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05898620	Phase 3	Active, not recruiting	Sponsor	NGNE	—	Rett Syndrome	—
NCT05228145	Phase 2	Active, not recruiting	Sponsor	NGNE	—	Neuronal Ceroid Lipofuscinosis CLN5	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Neurogene Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	1,362,456	no change	0.37%	2026-08-14
Baker Bros. Advisors	991,691	no change	0.16%	2026-08-14
ADAR1 Capital Management	7,800	+7,800	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NGNE — Neurogene Inc.